← All trials
NCT04505566
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 9, 2020
- Primary completion
- Dec 31, 2025
- Completion date
- Dec 31, 2025
- First posted
- Aug 10, 2020
- Last posted
- Dec 14, 2020
- Enrollment
- 264
- Arms / groups
- 5 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Vanderbilt UniversityLead sponsor
- AllerganCollaborator
- National Eye Institute (NEI)Collaborator
- Vanderbilt UniversityOverall official - principal investigator
- Vanderbilt UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.